<DOC>
	<DOCNO>NCT00289926</DOCNO>
	<brief_summary>This study design evaluate efficacy safety oral Dehydroepiandrosterone ( DHEA ) 50mg daily , 12 month naturally menopausal woman low libido receive systemic oestrogen oestrogen- progestin therapy . Efficacy measure present study effect sexual function , wellbeing menopausal symptom . Safety measure include endometrial assessment transvaginal ultrasound ( TVU ) , vital sign , lipid profile , general electrolyte , effect glucose metabolism report adverse event .</brief_summary>
	<brief_title>Efficacy Safety Oral DHEA Therapy Postmenopausal Women Sexual Function , Wellbeing Vasomotor Symptoms</brief_title>
	<detailed_description>Dehydroepiandrosterone ( DHEA ) sulphate ( DHEAS ) abundant sex steroid woman . Dehydroepiandrosterone sulphate ( DHEAS ) , unique secretory product adrenal gland , DHEA convert various site body , brain , bone adipose tissue estrogen testosterone various by-product . DHEAS DHEA level decline age considerable conjecture result loss well-being libido . DHEA available over-the-counter nutritional supplement United States , increasingly prescribe formulate compound pharmacy across Australia . However , paucity data regard effect oral DHEA well-being , sexual function safety woman . Previous study evaluate effect DHEA either postmenopausal woman woman adrenal deficiency ( Addison 's disease ) produce conflict result , study find benefit term sexual function well-being study find benefit . Therefore , need appropriately power randomize control trial effect DHEA therapy sexual function well-being postmenopausal woman . In addition , DHEA may metabolize estrogen , whether DHEA alleviate vasomotor symptom merit evaluation . The effect DHEA endometrial ( uterine ) lining require assessment , give potential convert estrogen . The primary aim current study ass effect DHEA therapy naturally menopausal woman sexual function use Sabbatsberg Self-Rating Scale ( SSS ) 12 month randomize placebo control trial . In addition effect well-being assessed Psychological General Well-Being ( PGWB ) Index menopausal symptom evaluate Menopause Quality Life ( MENQOL ) Intervention Questionnaire . A diary record also employ assess effect sexual function . Safety assess entire study . Participants also undergo transvaginal ultrasound ( TVU ) begin end study , determine whether DHEA affect endometrial lining . This randomized , double-blind , placebo-controlled study conduct 240 woman 52-week period . Women randomize receive either placebo DHEA ( 50 mg/day ) 52-week period . It anticipate study require 6-month recruitment period . The study duration approximately 56 week , 4-week screening period treatment period 52 week . The study conduct approximately 13 month . This single-centre study conduct Alfred Hospital . Potential participant generally healthy woman age 40 - 65 year undergone natural menopause stable monogamous sexual relationship use hormone therapy ( HT ) . Participants require attend 6 clinic visit blind treatment period 52 week . Informed consent obtain participant prior commencement study procedure first clinic visit . If participant eligible , ask return end screen period randomize commence treatment . During treatment period , participant take one capsule daily ( placebo DHEA 50 mg ) . All participant return clinic 5 time , week 0 , 12 , 26 , 38 52 assessment efficacy safety . Blood test collect Weeks -4 , 0 , 12 , 26 52 ass safety hormone level . Prior commence study , participant require mammogram do within 12 month study entry . A transvaginal ultrasound perform assess endometrial thickness prior commencement trial . A Papanicolaou smear also perform cervix still present , woman Pap smear do within 12 month screen . These investigation , except mammogram Pap smear , repeat completion study . All participant complete physical examination include assessment vital sign , breast examination , internal external pelvic examination ass clitoromegaly ( clitoral enlargement ) . Skin evaluation scalp hair loss , hirsutism acne , assessment voice change make throughout study . Participants require complete various questionnaire assess sexual function ( SSS ) , menopausal symptom ( MENQUOL Intervention ) general well-being ( PGWB ) Weeks 0 , 12 , 26 52 . Participants also record satisfactory sexual event 28 day diary do 4 week prior Weeks 0 , 12 , 26 52 .</detailed_description>
	<mesh_term>Dehydroepiandrosterone</mesh_term>
	<criteria>Women : 1. 40 65 year age , least 12 month postmenopausal ( spontaneous menses last 12 month , age 55 year , hysterectomy one ovary situ folliclestimulating hormone [ FSH ] &gt; 20 IU/L . ( An FSH &gt; 20 IU/L also use confirm menopausal status nonhysterectomised woman &lt; 55 year , menopausal status unclear . ) 2. sexually active define involved form sexual activity least month . Women require partner . 3. body mass index ( BMI ) 1834 kg/m2 . 4. answer affirmatively follow question : In previous year find sexual activity satisfy ? Do feel experienced significant decrease desire interest ? Would like improvement desire interest sexual activity ? Would like treat ? 5 . Have clinically acceptable screen bilateral mammogram 6 . Have ≤ 4 mm endometrial double thickness abnormal finding TVU hysterectomised . 7 . Have clinically acceptable Pap smear cervix present , 8 . Be able willing participate study evidence provide write informed consent . 9. baseline DHEAS level &lt; 2.1 umol/L 1 . Have BMI &lt; 18 &gt; 34 kg/m2 2 . Dyspareunia alleviate use lubricant . 3 . Severe depression ( Beck Depression Inventory ScoreII [ BDI ] &gt; 20 ) . 4 . Have partnership problem . This establish interview ask follow question woman specific relationship : 1 . Are satisfied partner friend ? 2 . Do concern relationship ? 5 . Have use recent androgen therapy ( testosterone implant within last 28 week , transdermal testosterone cream within last 8 week , tibolone within last 12 week , oral testosterone within last 4 week inject testosterone within last 6 week ) . 6 . Have use treatment depression ( antidepressant , antipsychotic , antiepileptic ) within 2 month ) . 7 . Have know severe psychiatric illness . 8 . Have use estrogen , include vaginal conjugated equine estrogen , vaginal ring deliver 7.5 µg/day , estrogenprogestin combination last 2 month . ( Use Ovestin Vagifem pessary cream allow . ) 9 . Used phytoestrogens within 1 week prior Week 4 ( Visit 1 ) . ( Women allow participate trial , provide cease use phytoestrogens least 1 week visit 1 . ) 10 . Have renal disease , liver disease , epilepsy , diabetes mellitus major illness occur within last 6 month . 11 . Therapies know induce liver enzyme metabolism alter metabolism DHEA e.g . antiepileptic , dexamethasone , antituberculous drug . 12 . Undiagnosed genital bleeding . 13 . Have moderate severe acne hirsutism , use antiandrogen therapy acne hirsutism precede 5 year , androgenic alopecia . 14 . Active malignancy treatment malignancy precede 5 year ( exclude nonmelanotic skin cancer ) . 15 . Report alcohol consumption &gt; 3 standard drink per day . 16 . Have history cerebrovascular disease , thromboembolic disorder , myocardial infarction angina anytime study entry thrombophlebitis within last 5 year . 16 . An abnormal thyroidstimulating hormone ( TSH ) value screening ( however , participant abnormal TSH , normal free T4 free T3 clinical sign symptom thyroid disease , without replacement treatment , may admit study ) . 17 . Have abnormal liver function ( LFTs ) significant and/or ALT AST &gt; 3 time upper limit normal bilirubin &gt; 2 time upper limit normal .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>low libido</keyword>
	<keyword>lack wellbeing</keyword>
</DOC>